New regulatory recommendations on Richterʼs Esmya
Gedeon Richter Plc. announced Friday that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), as a conclusion of its review procedure related to Richterʼs drug Esmya, is recommending new measures to minimize the risk of rare but serious liver injury using Esmya for treatment of uterine fibroids.
According to a press release sent to the Budapest Business Journal, after considering all the evidence, the PRAC concluded that the medicine must not be used to treat women with liver problems, but that certain other patients may start new treatment courses provided they have regular liver tests.
Esmya is used to treat moderate to severe symptoms of uterine fibroids (benign tumors of the womb). The medicine has been shown to be effective at reducing bleeding and anaemia, as well as the size of the fibroids.
The PRAC has concluded that Esmya may have contributed to the development of some cases of serious liver injury. The committee has therefore made the following recommendations:
- Esmya must not be used in women with known liver problems.
- A liver function test should be performed before starting each treatment course and treatment must not be started if liver enzyme levels are more than two times the upper limit of normal.
- Liver function tests should be performed once a month during the first two treatment courses and two to four weeks after stopping treatment. If the test is abnormal (liver enzyme levels more than three times the upper limit of normal), the doctor should stop treatment and closely monitor the patient.
- Esmya should be used for more than one treatment course only in women who are not eligible for surgery. Women who are about to have surgery should continue to use one course.
- A card will be included in the box of the medicine to inform patients about the need for liver monitoring, and to contact their doctor should they develop symptoms of liver injury (such as tiredness, yellowing of the skin, darkening of the urine, nausea and vomiting).
- Studies should be performed to determine the effects of Esmya on the liver and whether these measures are effectively minimizing the risks.
In February 2018, while the review was ongoing, the PRAC issued temporary recommendations that no new patients should be started on Esmya. Having finalized its review, the committee has now concluded that new patients can start treatment in line with the above recommendations to minimize the risk of liver injury.
The PRAC’s recommendations will now be forwarded to the EMAʼs Committee for Medicinal Products for Human Use for the adoption of the body’s final opinion, and this will then go to the European Commission for a final legal decision. A letter will be sent to doctors to inform them of the new restrictions on use, which will become applicable once an EC decision is issued, the press release says.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.